Prolaio
We're Hiring!
Prolaio Company Growth, Stability & Outlook
What People Are Saying About Prolaio
-
Innovation-Driven Growth: Regulatory momentum is evident with FDA 510(k) clearance for the eVO2peak Module and references to multiple FDA-cleared algorithms, alongside ISO 13485 and MDSAP certifications. Ongoing clinical activity and datasets (e.g., OCORO Heart Study, multi‑million hours of heart data) point to a steadily expanding product and evidence base.
-
Strategic Partnerships: The March 27, 2025 acquisition by Kardigan integrates Prolaio’s FDA‑cleared software, curated CV datasets, and analytics into a larger R&D platform, signaling added resources and scope. Materials indicate Prolaio continues operating independently while benefiting from Kardigan’s broader heart‑health strategy.
-
Strong Hiring & Retention: Hiring signals are visible through an active careers page, a stated 32 new hires in 2025, and multiple current openings across functions. Employer recognition such as “Best Places to Work 2026” and ongoing recruiting activity suggest team expansion and brand momentum.
